Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
OncoCyte Corp (OCX)
NASDAQ:OCX
Holding OCX?
Track your performance easily
Earnings Data
Report Date
Mar 27, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.4Last Year’s EPS
-2.27Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 13, 2018
|% Change Since: -30.67%
|Next Earnings Date:Aug 14, 2018
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with significant progress in global expansion and strong investor support. There are challenges related to new instrument adoption and pre-revenue status, but the company's strategic initiatives and community support indicate promising potential for future growth.Company Guidance
In the third quarter of 2024, Oncocyte made significant strides in the transplant market, with their GraftAssure RUO kit test gaining traction, particularly in Europe where demand exceeded expectations. The company successfully signed top transplant centers in the U.S. and Germany, reinforcing their market leadership and setting a goal to have 20 sites signed by the end of next year, each potentially generating about $1 million annually in high-margin recurring clinical test kit revenue. They also progressed in their FDA program, with plans to meet with the FDA in early December to discuss their validation plan. Oncocyte raised $10.2 million in gross proceeds from a private placement, enhancing their ability to pursue FDA clearance and strategic partnerships, while maintaining a focus on tightly controlling expenses. Their digital PCR-based assay, noted for its ease of use and speed, is seen as a differentiator in the market, and they are actively pursuing strategic partnerships to further expand their reach. Additionally, favorable data from Milan validated their DetermaIO product, bringing them closer to reimbursement and enhancing its market potential in oncology diagnostics.Global Expansion of Transplant Testing
Oncocyte's tests are now being run on 3 continents with leading transplant centers signed up in key markets. The company is building market leadership and clinical data generation while making significant progress in its FDA program.
Successful Launch of GraftAssure
After launching GraftAssure, Oncocyte signed top transplant centers in the U.S. and Germany, indicating strong market demand and potential for high-margin recurring revenue.
Positive Response from the Transplant Community
The transplant community has shown a positive response to Oncocyte's efforts, supporting the democratization of transplant testing and indicating a shift towards local patient care.
Strong Investor Support and Capital Raising
Oncocyte raised $10.2 million in gross proceeds from a private placement with support from existing and new investors, including strategic partner Bio-Rad, without any discount to the closing price.
Innovative Pipeline in Oncology
The DetermaIO product showed favorable data in Milan, outperforming standard of care biomarkers and assays, with ongoing efforts to secure reimbursement and global market access.
---
OCX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
OCX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $3.00 | $2.94 | -2.00% |
| Aug 08, 2024 | $3.08 | $3.12 | +1.30% |
| May 15, 2024 | $2.95 | $3.07 | +4.07% |
| Apr 12, 2024 | $2.96 | $2.71 | -8.45% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does OncoCyte Corp (OCX) report earnings?
OncoCyte Corp (OCX) is schdueled to report earning on Mar 27, 2025, TBA Not Confirmed.
What is OncoCyte Corp (OCX) earnings time?
OncoCyte Corp (OCX) earnings time is at Mar 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is OCX EPS forecast?
OCX EPS forecast for the fiscal quarter 2024 (Q4) is -0.4.
---